Concomitant administration of gefitinib and acid-reducing agents affect the clinical outcome of advanced Non-Small-Cell Lung Cancer (NSCLC) patients
- At: 2013 FIP Congress in Dublin (Ireland)
- Type: Poster
- By: HU, Chun-Liang (Tainan Municipal Hospital, Pharmacy, Tainan, China Taiwan)
- Co-author(s): Lin, Sheng-Kai (Tainan Municipal Hospital, Tainan, China Taiwan)
Lee, Yang-Chen (Tainan Municipal Hospital, Tainan, China Taiwan)
Gefitinib, a tyrosine kinase inhibitors, used to treat advanced NSCLC patients in Taiwan. Drugs that cause significant sustained elevation in gastric pH may reduce plasma concentrations of gefitinib and therefore theoretically may reduce efficacy. The clinical relevance of this pharmacokinetic effect whether it actually leads to.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.